PV Bulletin

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

The Emergency Task Force of the EMA has recommended that marketing authorisation holders update their COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign due to decreased efficacy of existing vaccines.

Primary source: European Medicines Agency (EMA)

PV Impact Brief

MonitoringConfidence: high

What changed

ETF recommended that marketing authorisation holders update their COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign.

Why it matters

Decreased efficacy of existing vaccines against the XFG variant could reduce protection against COVID-19, necessitating vaccine strain updates.

Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

quarterly

Regulatory action details

Action type
Regulatory Recommendation / Public Health Communication
Publication date
2026-05-29
Last updated
2026-05-29
Safety issue
Decreased efficacy of existing vaccines against the evolving XFG variant of COVID-19.

Affected products

  • COVID-19 vaccines
    Marketing authorisation holders (various)

PV internal implications

Requires monitoring of vaccine efficacy signals and potential preparation for strain change variations.

View regulator source

Evidence and confidence

Confidence: highSource updated: May 29, 2026

Full briefing

Practical implication

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

The EMA ETF recommends updating COVID-19 vaccines to target the XFG variant for the 2026/2027 campaign, citing decreased efficacy of current vaccines against the evolving variant.

What changed: ETF recommended that marketing authorisation holders update their COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign.

Why it matters: Decreased efficacy of existing vaccines against the XFG variant could reduce protection against COVID-19, necessitating vaccine strain updates.

Practical implication: Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals#Vaccine Updates#Regulatory Recommendation / Public Health Communication#European Medicines Agency (EMA)#other#firecrawl-agent#regulatory-extraction

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward